Sign in to continue:

Friday, April 3rd, 2026

Singapore Market Outlook 2026: Top Stocks, Fund Flows & CapitaLand Insights – Weekly Financial Review


Broker Name: Lim & Tan Securities
Date of Report: 7 January 2026

Excerpt from Lim & Tan Securities report

  • Singapore’s FSSTI Index showed gains YTD, tracking positive global equity performance, while lower interest rates are expected to benefit major Singapore REITs and real estate players.
  • CapitaLand Integrated Commercial Trust (CICT) and CapitaLand Investment Limited (CLI) are highlighted for resilient performance, strong capital management, high occupancy rates, and ongoing asset enhancement initiatives.
  • CICT maintains a Singapore-centric portfolio with a market cap of S\$18.2bn, offering a 5.8% dividend yield and consensus target price upside, leading to an “Accumulate” rating.
  • CLI focuses on accelerating growth, capital efficiency, and operational excellence, supported by robust fundraising, prudent debt management, and ongoing portfolio optimization efforts.
  • Macro outlooks suggest that lower global interest rates will support both equities and bonds, with Singapore REITs likely to benefit from cheaper funding and acquisition opportunities.
  • Recent fund flows show institutional investors selling while retail investors are net buyers in Singapore equities, with sector trends detailed for December 2025.
  • Share buybacks and insider transactions are reported for various companies, alongside a schedule of dividend and special distribution dates for major Singapore stocks.

Above is an excerpt from a report by Lim & Tan Securities. Clients of Lim & Tan Securities can be the first to access the full report from the Lim & Tan Securities website : https://www.limtan.com.sg

Trip.com Poised for Strong Outbound Travel Growth Amid Global Expansion and Holiday Demand Surge

Date: September 19, 2024Broker: China Galaxy InternationalTa...

Simba to Acquire M1: How Singapore Telco Consolidation Benefits Singtel and StarHub 1

Broker: Maybank Research Pte Ltd Date of Report: August 11, ...

Akeso, Inc. (9926 HK): A Revolutionary Player in Lung Cancer Treatment

Akeso, Inc. (9926 HK): A Revolutionary Player in Lung Cancer...

   Ad